Focus on PD-1/PD-L1-Targeting Antibodies in Colorectal Cancer: Are There Options Beyond Dostarlimab, Nivolumab, and Pembrolizumab? A Comprehensive Review

Focus on PD-1/PD-L1-Targeting Antibodies in Colorectal Cancer: Are There Options Beyond Dostarlimab, Nivolumab, and Pembrolizumab? A Comprehensive Review

The PD-1/PD-L1 pathway has emerged as a critical target in colorectal cancer (CRC) immunotherapy, with pembrolizumab, nivolumab, and dostarlimab demonstrating significant clinical efficacy, particularly in microsatellite instability-high (MSI-H) and mismatch repair-deficient (dMMR) tumors. However,...

Full description

Saved in:
Bibliographic Details
Main Authors: Mateusz Kciuk, Katarzyna Wanke, Weronika Kruczkowska, Beata Marciniak, Renata Kontek
Format: Article
Language:English
Published: MDPI AG 2025-06-01
Series:Molecules
Subjects:
antibodies
colorectal cancer
immunotherapy
programmed cell death
Online Access:https://www.mdpi.com/1420-3049/30/13/2686
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1420-3049/30/13/2686

Similar Items